MicroRNA-1179 targets Epiregulin (EREG) regulates the proliferation and metastasis of human multiple myeloma cells.

MicroRNA-1179 (miRNA-1179) is an extensively studied tumor suppressor. however, the significance of miR-1179 in multiple myeloma has not been investigated previously. So, there is a need for research to find out about the significance of miR-1179 in multiple myeloma. However, current investigations have examined the significance of miRNA-1179 in multiple myeloma for the first time by targeting epiregulin (EREG). In this study, 26 multiple myeloma specimens and 16 healthy donor specimens were examined. Multiple myeloma cell lines (U266, RPMI-8226, KMS-11, JJN-3, and IM-9) were used. In this study, expression analysis, cell viability, colony formation assay, and transwell assay were carried out by standard methods. The outcomes revealed the downregulation of miRNA-1179 in multiple myeloma. Overexpression of miRNA-1179 promotes, while its inhibition suppresses, the survival ability and colony formation of the U266 multiple myeloma cells. Investigation of underlying mechanisms revealed apoptosis to be responsible for the tumour-suppressive effects of miRNA-1179. The proportion of apoptosis in U266 cells rose from 5.32% to 34.86% when miRNA-1179 was overexpressed. Additionally, it was discovered that miRNA-1179 directs its tumor-inhabiting activities toward EREG at the molecular level. While EREG knockdown was found to halt the proliferation of U266 cells, its overexpression could overcome the suppressive effects of miRNA-1179 on the survival ability, mobility, and invasion of the U266 cells. This research proves that miRNA-1179 can be used as a new treatment or drug for multiple myeloma.